These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11306151)

  • 41. A web application for evaluating Phase I methods using a non-parametric optimal benchmark.
    Wages NA; Varhegyi N
    Clin Trials; 2017 Oct; 14(5):553-557. PubMed ID: 28649874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
    Sharma MR; Ratain MJ
    Clin Cancer Res; 2016 Feb; 22(3):527-9. PubMed ID: 26467385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.
    Bartroff J; Lai TL; Narasimhan B
    Stat Med; 2014 Jul; 33(16):2718-35. PubMed ID: 24577750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.
    Ursino M; Zohar S; Lentz F; Alberti C; Friede T; Stallard N; Comets E
    Biom J; 2017 Jul; 59(4):804-825. PubMed ID: 28321893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology.
    Altzerinakou MA; Paoletti X
    Stat Methods Med Res; 2020 Feb; 29(2):508-521. PubMed ID: 30945604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An adaptive model switching approach for phase I dose-finding trials.
    Daimon T; Zohar S
    Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A statistical evaluation of dose expansion cohorts in phase I clinical trials.
    Boonstra PS; Shen J; Taylor JM; Braun TM; Griffith KA; Daignault S; Kalemkerian GP; Lawrence TS; Schipper MJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity equivalence range design (TEQR): a practical Phase I design.
    Blanchard MS; Longmate JA
    Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential designs for logistic phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.